Physician profile
Yan Wu
NPI 1831191550
$12,719.94
in general payments reported to CMS, 2019-2025
35 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,234 · 2020: $847 · 2021: $1,258 · 2022: $1,733 · 2023: $1,857 · 2024: $1,797 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,510 · Gift: $59.40 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $29.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,509.60 |
| Gift | $59.40 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $29.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,990.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,846.40 | 2019-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $1,282.62 | 2021-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Amneal Pharmaceuticals LLC | $985.55 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $894.28 | 2022-2025 | |
| Novo Nordisk INC | $839.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $727.14 | 2019-2025 | |
| Mannkind Corporation | $725.98 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals Lp | $566.39 | 2019-2023 | Farxiga |
| Abbvie INC. | $326.14 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $314.97 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Horizon Therapeutics Plc | $249.79 | 2021-2023 | Tepezza |
| Corcept Therapeutics | $243.94 | 2019-2024 | Korlym |
| Medtronic, INC. | $236.95 | 2022-2025 | Minimed 780g |
| Amgen INC. | $235.08 | 2022-2025 | Tepezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $216.51 | 2020-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $176.61 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $116.05 | 2025 | Rezdiffra |
| Intra-Sana Laboratories | $111.11 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $105.78 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $61.78 | 2024-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $60.48 | 2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $58.69 | 2019 | |
| Shire North American Group INC | $50.48 | 2019 | |
| Embecta Corp. | $44.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Lifescan, INC. | $38.74 | 2022 | |
| Ibsa Pharma INC. | $37.60 | 2019-2021 | |
| Becton, Dickinson and Company | $36.34 | 2022 | |
| Insulet Corporation | $33.57 | 2023-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $26.31 | 2020-2025 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $24.37 | 2020 | |
| Amarin Pharma, INC. | $14.73 | 2020 | |
| Pfizer INC. | $14.51 | 2024 | |
| Antares Pharma, INC. | $14.21 | 2023 | Tlando, Xyosted, Nocdurna |
| Rhythm Pharmaceuticals, INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.